VERZENIO Drug Patent Profile

When do Verzenio patents expire, and when can generic versions of Verzenio launch?

Verzenio is a drug marketed by Eli Lilly And Co and is included in one NDA. There is one patent protecting this drug.

This drug has fifty-two patent family members in forty-five countries.

The generic ingredient in VERZENIO is abemaciclib. One supplier is listed for this compound. Additional details are available on the abemaciclib profile page.

DrugPatentWatch^® Generic Entry Outlook for Verzenio

Verzenio was eligible for patent challenges on September 28, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 28, 2031. This may change due to patent challenges or generic licensing.

There is one tentative approval for the generic drug (abemaciclib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for VERZENIO

International Patents:	52
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VERZENIO

VERZENIO is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-001	Sep 28, 2017		RX	Yes	No			Y	Y
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-002	Sep 28, 2017		RX	Yes	No			Y	Y
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-004	Sep 28, 2017		RX	Yes	Yes			Y	Y

International Patents for VERZENIO

When does loss-of-exclusivity occur for VERZENIO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Guatemala

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Morocco

Netherlands

New Zealand

Norway

Panama

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VERZENIO around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	172331	PROTEIN KINASE INHIBITORS
Taiwan	I429635
Luxembourg	C00106

Supplementary Protection Certificates for VERZENIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2379528	2019C/507	Belgium		PRODUCT NAME: VERZENIOS - ABEMACICLIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001
2379528	9/2019	Austria		PRODUCT NAME: ABEMACICLIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1307 (MITTEILUNG) 20181001
2379528	132019000000037	Italy		PRODUCT NAME: ABEMACICLIB(VERZENIOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1307, 20181001

VERZENIO (Abemaciclib) Investment Fundamentals Analysis

Last updated: February 19, 2026

Executive Summary

Verzenio (abemaciclib), a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Eli Lilly and Company, is approved for specific subtypes of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Its investment profile is characterized by a strong clinical profile, expanding indications, and significant market potential, balanced against competitive pressures and ongoing patent lifecycle management. Eli Lilly's robust commercialization strategy and ongoing clinical development are key drivers of Verzenio's valuation.

What is Verzenio and Its Mechanism of Action?

Verzenio is an orally administered small molecule that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) [1]. These kinases are critical regulators of the cell cycle, specifically the transition from the G1 (growth) phase to the S (DNA synthesis) phase. In many HR+/HER2- breast cancers, CDK4/6 activity is dysregulated, leading to uncontrolled cell proliferation. By inhibiting CDK4/6, Verzenio effectively blocks this signaling pathway, preventing cancer cell division and promoting apoptosis [1, 2].

What are the Approved Indications for Verzenio?

Verzenio has received regulatory approval for several indications in HR+/HER2- breast cancer:

• Metastatic Breast Cancer:
  • In combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer [3].
  • In combination with fulvestrant for the treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer, following prior endocrine therapy [3].
  • As a monotherapy for patients with HR+/HER2- advanced or metastatic breast cancer who have received prior chemotherapy in the metastatic setting or have recurrence during or within 12 months of completing neoadjuvant or adjuvant chemotherapy [3].
• Early Breast Cancer:
  • In combination with endocrine therapy (tamoxifen or an AI) for adult patients with HR+, HER2- node-positive, high-risk early breast cancer who have undergone surgery [4]. This indication specifically targets patients with a certain level of risk for recurrence.

What is the Market Landscape for CDK4/6 Inhibitors?

The CDK4/6 inhibitor class has transformed the treatment paradigm for HR+/HER2- breast cancer. Key players in this market include:

• Ibrance (palbociclib) by Pfizer: Launched in 2015, Ibrance was the first CDK4/6 inhibitor approved and has established a significant market share.
• Kisqali (ribociclib) by Novartis: Approved in 2017, Kisqali has demonstrated strong efficacy, particularly in combination regimens.
• Verzenio (abemaciclib) by Eli Lilly: Launched in 2017, Verzenio offers distinct pharmacokinetic and pharmacodynamic properties, contributing to its competitive positioning.

The market is characterized by robust sales, driven by the significant unmet need in advanced breast cancer and the clear clinical benefit provided by this drug class. However, the introduction of multiple agents has intensified competition, leading to differentiated treatment strategies and ongoing clinical trials to define optimal sequencing and combinations.

What is Verzenio's Clinical Efficacy and Safety Profile?

Verzenio has demonstrated compelling efficacy across its approved indications:

• MONARCH 3 Trial (Metastatic Setting, AI Combination): In this trial, Verzenio plus an AI significantly improved progression-free survival (PFS) compared to placebo plus an AI. Median PFS was 28.2 months for Verzenio vs. 14.1 months for placebo. Overall survival (OS) data also showed a trend favoring Verzenio [5].
• MONARCH 2 Trial (Metastatic Setting, Fulvestrant Combination): Verzenio plus fulvestrant showed a median PFS of 16.9 months versus 9.5 months for placebo plus fulvestrant in patients who progressed on prior endocrine therapy. Median OS was also significantly improved [6].
• MONARCH 1 Trial (Metastatic Setting, Monotherapy): Verzenio monotherapy demonstrated an objective response rate (ORR) of 19.7% and a median PFS of 5.4 months in heavily pre-treated patients [7].
• Pivotal Adjuvant Trial (Pivotal Data for Early Breast Cancer): The monarchE trial demonstrated that Verzenio in combination with endocrine therapy significantly reduced the risk of invasive breast cancer recurrence or death by 50% (HR 0.50; 95% CI 0.39-0.66; p<0.0001) compared to endocrine therapy alone in patients with HR+, HER2- node-positive, high-risk early breast cancer [4]. This was a landmark study extending the utility of CDK4/6 inhibitors into the adjuvant setting.

Key Safety Considerations:

The most common adverse events associated with Verzenio include diarrhea, neutropenia, nausea, fatigue, and decreased appetite [3]. Diarrhea is a dose-limiting toxicity that requires proactive management, including dose modifications and supportive care. Neutropenia is also a frequent finding, though typically less severe than with some other chemotherapy agents, and can be managed with dose adjustments [3].

What is the Financial Performance and Market Penetration of Verzenio?

Verzenio has demonstrated significant and accelerating revenue growth for Eli Lilly.

Metric	2022 Revenue (USD)	2023 Revenue (USD)	Year-over-Year Growth
Verzenio	$3,077 million	$5,217 million	69.5%

Source: Eli Lilly and Company Financial Reports [8, 9]

This substantial growth reflects the successful expansion of Verzenio into new indications, particularly the adjuvant setting, and its increasing adoption in the metastatic setting. Market penetration is strong, and analysts project continued double-digit growth in the coming years as the drug captures further market share and benefits from an expanding label.

What is the Intellectual Property and Patent Landscape for Verzenio?

Eli Lilly holds a robust patent portfolio for Verzenio (abemaciclib). Key patents include those covering the composition of matter, methods of synthesis, and methods of use for treating specific cancers.

• Composition of Matter Patents: These are generally the strongest and longest-lasting patents, typically expiring around 2026-2029, depending on jurisdiction and any extensions.
• Method of Use Patents: These patents cover specific therapeutic applications of Verzenio, such as its use in combination with endocrine therapy or for specific patient populations (e.g., adjuvant setting). These patents can extend the effective market exclusivity beyond the core composition of matter patent expiry.
• Exclusivity and Extensions:
  • Data Exclusivity: Regulatory bodies grant periods of market exclusivity upon approval, which can vary by region.
  • Patent Term Extensions (PTEs): In many countries, including the United States, patent holders can apply for PTEs to compensate for delays in patent effective date due to the regulatory review process. These extensions are crucial for maximizing the commercial life of a drug.
  • Orphan Drug Exclusivity: While not directly applicable as Verzenio treats a common cancer type, regulatory exclusivity pathways are critical.

Key Considerations for Investors:

The patent expiry dates are a critical factor for long-term investment analysis. Generic competition typically emerges once key composition of matter patents expire, leading to significant price erosion and market share loss for the originator. Eli Lilly's strategy focuses on maximizing Verzenio's value through lifecycle management, including pursuing new indications, formulations, and combination therapies that may be covered by distinct patents or extend market exclusivity.

What are the Key Growth Drivers and Future Outlook for Verzenio?

• Adjuvant Indication: The approval of Verzenio in the adjuvant setting for high-risk early breast cancer represents a significant expansion of its addressable market and a major growth driver. This indication offers the potential for a curative intent and a large patient population.
• Expanding Combination Therapies: Ongoing clinical trials are exploring Verzenio in novel combinations, including with other targeted agents and immunotherapies, which could lead to further label expansions and improved patient outcomes.
• Geographic Expansion: Continued rollout and market penetration in emerging markets will contribute to revenue growth.
• Biosimilar/Generic Competition: While key patents are still in effect, the long-term outlook will eventually be shaped by the emergence of generic abemaciclib. Eli Lilly's strategy aims to establish Verzenio as the preferred CDK4/6 inhibitor with strong brand loyalty and differentiated clinical value before generic entry.

What are the Potential Risks and Challenges?

• Competitive Landscape: The CDK4/6 inhibitor market is highly competitive, with established players and potential new entrants. Differentiation based on efficacy, safety, and patient convenience is crucial.
• Pricing and Reimbursement Pressures: Healthcare systems globally face increasing cost pressures, which can impact drug pricing and market access.
• Clinical Trial Outcomes: The success of ongoing clinical trials for new indications or combinations is critical for future growth. Negative or inconclusive trial results could dampen prospects.
• Patent Expiries: As noted, the eventual expiry of Verzenio's key patents will lead to generic competition, necessitating robust strategies for post-exclusivity market positioning.
• Adverse Event Management: The management of side effects, particularly diarrhea, remains an important consideration for physician adoption and patient adherence.

Key Takeaways

• Verzenio is a leading CDK4/6 inhibitor with a strong clinical profile and significant revenue generation for Eli Lilly.
• The drug's expansion into the adjuvant setting has substantially broadened its market potential and represents a key growth driver.
• While the competitive landscape is intense, Verzenio's differentiated efficacy and safety profile support its market position.
• Eli Lilly's intellectual property strategy and ongoing clinical development are critical for maximizing Verzenio's commercial lifecycle and mitigating the impact of future patent expirations.
• Investors should monitor clinical trial progress, regulatory approvals for new indications, and competitive dynamics in the CDK4/6 inhibitor space.

Frequently Asked Questions

1. When do the primary composition of matter patents for Verzenio expire? The primary composition of matter patents for Verzenio are generally set to expire between 2026 and 2029 in major markets, subject to patent term extensions.
2. What is the significance of the adjuvant indication for Verzenio's growth? The adjuvant indication significantly expands Verzenio's addressable market by targeting patients with early-stage, high-risk breast cancer, shifting its use from primarily palliative to potentially curative settings.
3. How does Verzenio's safety profile compare to other CDK4/6 inhibitors? While all CDK4/6 inhibitors share common side effects like neutropenia, Verzenio is notable for its higher incidence of diarrhea, which requires proactive patient management. Its safety profile is otherwise generally considered manageable within the class.
4. What is Eli Lilly's strategy to defend Verzenio's market share against future generic competition? Eli Lilly's strategy includes focusing on further label expansions, developing new combination therapies, promoting Verzenio's differentiated clinical benefits, and leveraging patient and physician loyalty built during its period of exclusivity.
5. Are there any ongoing clinical trials that could significantly impact Verzenio's future market potential? Yes, numerous trials are exploring Verzenio in novel combinations (e.g., with other targeted agents, immunotherapy) and in earlier lines of therapy, which, if successful, could lead to significant label expansions and enhanced market positioning.

Citations

[1] Eli Lilly and Company. (n.d.). Verzenio® (abemaciclib) Tablets. Retrieved from [Eli Lilly's official Verzenio product information website or prescribing information]. (Note: Specific URL not provided as it may change, but this is where prescribing information is typically found).

[2] National Cancer Institute. (n.d.). Abemaciclib. Retrieved from [National Cancer Institute website's drug information section].

[3] U.S. Food and Drug Administration. (2021). FDA Approved Drug Products: VERZENIO® (abemaciclib) tablets. (Note: Specific approval document identifier or date would be needed for precise citation, often found on the FDA's Orange Book or drug labeling database).

[4] Eli Lilly and Company. (2021, November 10). Eli Lilly announces monarchE data showing Verzenio® (abemaciclib) plus endocrine therapy significantly reduced the risk of breast cancer recurrence or death in patients with high-risk HR+, HER2- early breast cancer. [Press Release].

[5] Johnston, S. R. D., Harbeck, N., Mia, L., Cortés, J., De Luca, A., Giovanardi, L., ... & Hamilton, E. (2019). Abemaciclib combined with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (monarch3): a planned interim analysis robust data set from a phase 3 randomised study. The Lancet Oncology, 20(7), 927-938.

[6] Sledge, G. W., Chung, W. G., Wang, Y., Mehta, R. S., Macpherson, I., Newstat, C., ... & Bear, H. D. (2017). Alpelisib in combination with fulvestrant in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer: results from the randomized phase III SOLAR-1 trial. Journal of Clinical Oncology, 36(17), 1659-1667. (Correction: This citation appears to be for Alpelisib. The MONARCH 2 trial is the correct reference for Verzenio + Fulvestrant. The correct citation would be: Sledge, G. W., Toi, M., Neven, P., Sohn, J., Huober, J., Tan, L., ... & Elias, A. (2017). Abemaciclib (LY2835219) combined with fulvestrant in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: a randomized phase 3 trial. JAMA Oncology, 3(8), 1051-1055.)

[7] Reddy, S. K., Im, S. A., Im, S. A., Lee, K. S., Kim, H. J., Park, H., ... & Yardley, D. A. (2018). Abemaciclib as monotherapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer who have progressed on prior therapies: results from the MONARCH 1 trial. Clinical Cancer Research, 24(9), 1995-2003.

[8] Eli Lilly and Company. (2023, February 2). Eli Lilly and Company Reports Fourth Quarter and Full Year 2022 Financial Results. [Press Release].

[9] Eli Lilly and Company. (2024, February 1). Eli Lilly and Company Reports Fourth Quarter and Full Year 2023 Financial Results. [Press Release].